<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="145603">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01205152</url>
  </required_header>
  <id_info>
    <org_study_id>ENB-003-08</org_study_id>
    <secondary_id>FD-R-003745-03</secondary_id>
    <nct_id>NCT01205152</nct_id>
  </id_info>
  <brief_title>Extension Study of Protocol ENB-002-08 - Study of Asfotase Alfa in Infants and Young Children With Hypophosphatasia (HPP)</brief_title>
  <official_title>Extension Study of ENB-0040 (Human Recombinant Tissue Nonspecific Alkaline Phosphatase Fusion Protein) in Severely Affected Infants and Young Children With Hypophosphatasia (HPP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexion Pharma GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexion Pharma GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial studies the long term safety and efficacy of asfotase alfa in infants
      and young children with infantile onset HPP who completed the ENB-002-08 study.

      Partial funding for this study was provided by the Office of Orphan Product Development
      (OOPD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Asfotase Alfa was formerly referred to as ENB-0040

      Hypophosphatasia (HPP) is a life-threatening, genetic, and ultra-rare metabolic disease
      characterized by defective bone mineralization and impaired phosphate and calcium regulation
      that can lead to progressive damage to multiple vital organs, including destruction and
      deformity of bones, profound muscle weakness, seizures, impaired renal function, and
      respiratory failure. There are no approved disease-modifying treatments for patients with
      this disease. There is also limited data available on the natural course of this disease
      over time, particularly in patients with the juvenile-onset form.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the long-term tolerability of subcutaneous (SC) asfotase alfa</measure>
    <time_frame>84 months</time_frame>
    <description>The time points will be pre-dose (Baseline from the ENB-002-08 study) to Month 84 of the ENB-003-08 study which represents 90 months.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To assess the long-term efficacy of asfotase alfa in treating rickets in infants and young children with HPP</measure>
    <time_frame>84 Months</time_frame>
    <description>The time points will be pre-dose (Baseline from ENB-002-08 study) to Month 84 of the ENB-003-08 study which represents 90 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the long-term pharmacodynamics (PD) of SC asfotase alfa</measure>
    <time_frame>84 Months</time_frame>
    <description>The time points will be pre-dose (baseline from the ENB-002-08 study) to Month 84 of the ENB-003-08 study whih represents 90 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the effect of SC asfotase alfa on growth and development</measure>
    <time_frame>84 Months</time_frame>
    <description>The time points will be pre-dose (Baseline from the ENB-002-08 study) to Month 84 in the ENB-003-08 study which represents 90 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the effect of SC asfotase alfa on survival, respiratory function, and other clinical signs and symptoms of HPP in infants and young children</measure>
    <time_frame>84 Months</time_frame>
    <description>The time points will be pre-dose (Baseline from the ENB-002-08 study) to Month 84 of the ENB-003-08 study which represents 90 months.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Hypophosphatasia</condition>
  <arm_group>
    <arm_group_label>asfotase alfa</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>asfotase alfa</intervention_name>
    <arm_group_label>asfotase alfa</arm_group_label>
    <other_name>ENB-0040</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Patient completed participation in ENB-002-08

          -  Written informed consent by parent or other legal guardian prior to any study
             procedures being performed

          -  Parent or other legal guardian willing to comply with study requirements

        Exclusion Criteria

          -  History of sensitivity to any of the constituents of the study drug

          -  Clinically significant disease that precludes study participation

          -  Enrollment in any study involving an investigational drug, device, or treatment for
             HPP(e.g., bone marrow transplantation)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>42 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>St. John's Medical Research Institute</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Univesity Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent Hospital</name>
      <address>
        <city>Green Bay</city>
        <state>Wisconsin</state>
        <zip>54301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tawam Hospital</name>
      <address>
        <city>Al Ain</city>
        <state>Abu-Dhabi</state>
        <country>United Arab Emirates</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Belfast Hospital for Sick Children</name>
      <address>
        <city>Belfast</city>
        <state>Northern Ireland</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sheffield Children's Hospital</name>
      <address>
        <city>Sheffield</city>
        <zip>S10 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Arab Emirates</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.hypophosphatasia.com</url>
    <description>Hypophosphatasia Website</description>
  </link>
  <link>
    <url>http://www.hypophosphatasia.com/hcp/</url>
    <description>Hypophosphatasia Website for Healthcare Providers</description>
  </link>
  <link>
    <url>http://www.hypophosphatasie.com</url>
    <description>Hypophosphatasie Europe</description>
  </link>
  <link>
    <url>http://www.magicfoundation.org</url>
    <description>HPP support group</description>
  </link>
  <link>
    <url>http://health.groups.yahoo.com/group/Hyphosphatasia</url>
    <description>Yahoo health group for HPP with an international list serve where patients can correspond and post questions to the group</description>
  </link>
  <link>
    <url>http://www.softbones.org</url>
    <description>US Hypophosphatasia Group (Soft Bones)</description>
  </link>
  <verification_date>September 2016</verification_date>
  <lastchanged_date>September 27, 2016</lastchanged_date>
  <firstreceived_date>September 17, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypophosphatasia</keyword>
  <keyword>HPP</keyword>
  <keyword>Bone Disease</keyword>
  <keyword>Soft Bones</keyword>
  <keyword>Low Alkaline Phosphatase</keyword>
  <keyword>genetic metabolic disorder</keyword>
  <keyword>alkaline phosphatase</keyword>
  <keyword>tissue non-specific alkaline phosphatase</keyword>
  <keyword>rickets</keyword>
  <keyword>osteomalacia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypophosphatasia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
